{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:11:36Z","timestamp":1787991096721,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This study was supported by Science Foundation of the Fujian Province","award":["No.2021J010289; No.2023J011473"],"award-info":[{"award-number":["No.2021J010289; No.2023J011473"]}]},{"name":"This study was supported by Science Foundation of the Fujian Province","award":["No.2021J010289; No.2023J011473"],"award-info":[{"award-number":["No.2021J010289; No.2023J011473"]}]},{"name":"This study was supported by Science Foundation of the Fujian Province","award":["No.2021J010289; No.2023J011473"],"award-info":[{"award-number":["No.2021J010289; No.2023J011473"]}]},{"name":"This study was supported by Science Foundation of the Fujian Province","award":["No.2021J010289; No.2023J011473"],"award-info":[{"award-number":["No.2021J010289; No.2023J011473"]}]},{"name":"This study was supported by Science Foundation of the Fujian Province","award":["No.2021J010289; No.2023J011473"],"award-info":[{"award-number":["No.2021J010289; No.2023J011473"]}]},{"name":"This study was supported by Science Foundation of the Fujian Province","award":["No.2021J010289; No.2023J011473"],"award-info":[{"award-number":["No.2021J010289; No.2023J011473"]}]},{"name":"This study was supported by Science Foundation of the Fujian Province","award":["No.2021J010289; No.2023J011473"],"award-info":[{"award-number":["No.2021J010289; No.2023J011473"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-78656-0","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T08:45:07Z","timestamp":1731141907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate"],"prefix":"10.1038","volume":"14","author":[{"given":"Shenglong","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyuan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Defu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"key":"78656_CR1","volume-title":"Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries (World Health Organization, 2024)."},{"key":"78656_CR2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"Global","year":"2022","unstructured":"Global & national burden of hepatitis B. 1990\u20132019: a systematic analysis for the global burden of Disease Study 2019. Lancet Gastroenterol. Hepatol. 7, 796\u2013829 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"78656_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3350\/cmh.2020.0049","volume":"26","author":"HJ Yim","year":"2020","unstructured":"Yim, H. J. et al. Comparison of clinical practice guidelines for the management of chronic hepatitis b: when to start, when to change, and when to stop. Clin. Mol. Hepatol. 26, 411\u2013429 (2020).","journal-title":"Clin. Mol. Hepatol."},{"key":"78656_CR4","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40261-021-01081-y","volume":"41","author":"L Brunet","year":"2021","unstructured":"Brunet, L. et al. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in people living with HIV: lipid changes and statin underutilization. Clin. Drug Invest. 41, 955\u2013965 (2021).","journal-title":"Clin. Drug Invest."},{"key":"78656_CR5","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1097\/QAD.0000000000003245","volume":"36","author":"KJ Kauppinen","year":"2022","unstructured":"Kauppinen, K. J., Aho, I. & Sutinen, J. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain. Aids. 36, 1337\u20131344 (2022).","journal-title":"Aids"},{"key":"78656_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1089\/apc.2019.0236","volume":"33","author":"KJ Kauppinen","year":"2019","unstructured":"Kauppinen, K. J., Kivel\u00e4, P. & Sutinen, J. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide significantly worsens the lipid Profile in a Real-World setting. AIDS Patient Care STDS. 33, 500\u2013506 (2019).","journal-title":"AIDS Patient Care STDS"},{"key":"78656_CR7","doi-asserted-by":"publisher","first-page":"ofz414","DOI":"10.1093\/ofid\/ofz414","volume":"6","author":"JJ Schafer","year":"2019","unstructured":"Schafer, J. J. et al. Changes in body Mass Index and atherosclerotic disease risk score after switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide. Open. Forum Infect. Di. 6, ofz414 (2019).","journal-title":"Open. Forum Infect. Di"},{"key":"78656_CR8","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1097\/QAD.0000000000002350","volume":"33","author":"A Milinkovic","year":"2019","unstructured":"Milinkovic, A., Berger, F., Arenas-Pinto, A. & Mauss, S. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS. 33, 2387\u20132391 (2019).","journal-title":"AIDS"},{"key":"78656_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal, K. et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J. Hepatol. 68, 672\u2013681 (2018).","journal-title":"J. Hepatol."},{"key":"78656_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17765","author":"PN Cheng","year":"2023","unstructured":"Cheng, P. N. et al. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B. Aliment. Pharm. Ther. https:\/\/doi.org\/10.1111\/apt.17765 (2023).","journal-title":"Aliment. Pharm. Ther."},{"key":"78656_CR11","doi-asserted-by":"crossref","unstructured":"Eg, H., Ea, J., Jj, Y., Sg, K. & Ys, K. Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. Hep. Intl. 17, (2023).","DOI":"10.1007\/s12072-023-10528-7"},{"key":"78656_CR12","doi-asserted-by":"crossref","unstructured":"Rm, L. et al. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients. World J. Hepatol. 15, (2023).","DOI":"10.4254\/wjh.v15.i8.964"},{"key":"78656_CR13","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.3748\/wjg.v29.i44.5907","volume":"29","author":"WT Peng","year":"2023","unstructured":"Peng, W. T. et al. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: a real-world study. World J. Gastroentero. 29, 5907\u20135918 (2023).","journal-title":"World J. Gastroentero"},{"key":"78656_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12872-022-02706-6","volume":"22","author":"T Sun","year":"2022","unstructured":"Sun, T. et al. Predictive value of LDL\/HDL ratio in coronary atherosclerotic heart disease. Bmc Cardiovasc. Disor. 22, 273 (2022).","journal-title":"Bmc Cardiovasc. Disor"},{"key":"78656_CR15","first-page":"1309","volume":"30","author":"Chinese Society of Hepatology, Chinese Medical Association & Chinese Society of Infectious Diseases, Chinese Medical Association","year":"2022","unstructured":"Chinese Society of Hepatology, Chinese Medical Association & Chinese Society of Infectious Diseases, Chinese Medical Association. [Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)]. Zhonghua Gan Zang Bing Za Zhi. 30, 1309\u20131331 (2022).","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"78656_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000519440","volume":"65","author":"S Jeong","year":"2022","unstructured":"Jeong, S., Shin, H. P. & Kim, H. I. Real-world single-center comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in patients with chronic Hepatitis B. Intervirology. 65, 94\u2013103 (2022).","journal-title":"Intervirology"},{"key":"78656_CR17","doi-asserted-by":"crossref","unstructured":"K, S. et al. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PloS One 17, (2022).","DOI":"10.1371\/journal.pone.0261760"},{"key":"78656_CR18","doi-asserted-by":"publisher","first-page":"135965352210823","DOI":"10.1177\/13596535221082399","volume":"27","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: a prospective real-world clinical study. Antivir Ther. 27, 13596535221082399 (2022).","journal-title":"Antivir Ther."},{"key":"78656_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jfma.2021.09.009","volume":"121","author":"ML Yeh","year":"2022","unstructured":"Yeh, M. L. et al. Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide. J. Formos. Med. Assoc. 121, 1273\u20131282 (2022).","journal-title":"J. Formos. Med. Assoc."},{"key":"78656_CR20","unstructured":"Cardiovascular diseases (CVDs). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)."},{"key":"78656_CR21","doi-asserted-by":"crossref","unstructured":"Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366, 1267\u20131278 (2005).","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"78656_CR22","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1001\/archinte.161.22.2685","volume":"161","author":"I Lemieux","year":"2001","unstructured":"Lemieux, I. et al. Total Cholesterol\/HDL Cholesterol Ratio vs LDL Cholesterol\/HDL Cholesterol Ratio as indices of ischemic heart Disease Risk in men: the Quebec Cardiovascular Study. Arch. Intern. Med. 161, 2685\u20132692 (2001).","journal-title":"Arch. Intern. Med."},{"key":"78656_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12872-019-1228-7","volume":"19","author":"S Calling","year":"2019","unstructured":"Calling, S., Johansson, S. E., Wolff, M., Sundquist, J. & Sundquist, K. The ratio of total cholesterol to high density lipoprotein cholesterol and myocardial infarction in women\u2019s health in the Lund area (WHILA): a 17-year follow-up cohort study. Bmc Cardiovasc. Disor. 19, 239 (2019).","journal-title":"Bmc Cardiovasc. Disor"},{"key":"78656_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HLY Chan","year":"2016","unstructured":"Chan, H. L. Y. et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol. Hepatol. 1, 185\u2013195 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"78656_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti, M. et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol. Hepatol. 1, 196\u2013206 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"78656_CR26","doi-asserted-by":"crossref","unstructured":"J, L. et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-na\u00efve chronic hepatitis B. Liver Int. 42, (2022).","DOI":"10.1111\/liv.15261"},{"key":"78656_CR27","unstructured":"Young-Suk Lim. Long-term Safety Profile of Tenofovir Alafenamide in Chronic Hepatitis B patients: final 8-Year results of 2 phase 3 studies. (2023). https:\/\/www.natap.org\/2023\/EASL\/EASL_117.htm"},{"key":"78656_CR28","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/apt.16595","volume":"54","author":"Q Zheng","year":"2021","unstructured":"Zheng, Q. et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment. Pharm. Ther. 54, 1100\u20131109 (2021).","journal-title":"Aliment. Pharm. Ther."},{"key":"78656_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3350\/cmh.2022.0422","volume":"29","author":"SC Huang","year":"2023","unstructured":"Huang, S. C. & Liu, C. J. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: challenges and perspectives. Clin. Mol. Hepatol. 29, 320\u2013331 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"78656_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/hep.30857","volume":"71","author":"HSJ Choi","year":"2020","unstructured":"Choi, H. S. J. et al. Nonalcoholic steatohepatitis is Associated with Liver-related outcomes and all-cause Mortality in Chronic Hepatitis B. Hepatology. 71, 539\u2013548 (2020).","journal-title":"Hepatology"},{"key":"78656_CR31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/jgh.13536","volume":"32","author":"AWH Chan","year":"2017","unstructured":"Chan, A. W. H. et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J. Gastroen Hepatol. 32, 667\u2013676 (2017).","journal-title":"J. Gastroen Hepatol."},{"key":"78656_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-020-01750-3","author":"S Kazuharu","year":"2021","unstructured":"Kazuharu, S. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36\/PPAR-alpha activation in hepatitis B virus infection. J. Gastroenterol. https:\/\/doi.org\/10.1007\/s00535-020-01750-3 (2021).","journal-title":"J. Gastroenterol."},{"key":"78656_CR33","first-page":"184","volume":"18","author":"B Aloy","year":"2016","unstructured":"Aloy, B. et al. Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the kidneys? AIDS Rev. 18, 184\u2013192 (2016).","journal-title":"AIDS Rev."},{"key":"78656_CR34","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/hep.26714","volume":"59","author":"J Xu","year":"2014","unstructured":"Xu, J. et al. Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. Hepatology. 59, 1761\u20131771 (2014).","journal-title":"Hepatology"},{"key":"78656_CR35","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/hep.25961","volume":"56","author":"AD Quiroga","year":"2012","unstructured":"Quiroga, A. D. et al. Deficiency of carboxylesterase 1\/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia. Hepatology. 56, 2188\u20132198 (2012).","journal-title":"Hepatology"},{"key":"78656_CR36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3350\/cmh.2021.0314","volume":"28","author":"J Jeong","year":"2022","unstructured":"Jeong, J., Shin, J. W., Jung, S. W., Park, E. J. & Park, N. H. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis. Clin. Mol. Hepatol. 28, 254\u2013264 (2022).","journal-title":"Clin. Mol. Hepatol."},{"key":"78656_CR37","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","volume":"69","author":"J Bosch","year":"2020","unstructured":"Bosch, J., Gracia-Sancho, J. & Abraldes, J. G. Cirrhosis as new indication for statins. Gut. 69, 953\u2013962 (2020).","journal-title":"Gut"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78656-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78656-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78656-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T09:03:06Z","timestamp":1731142986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78656-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["78656"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-78656-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27369"}}